Wealthcare Advisory Partners LLC Purchases 2,598 Shares of Illumina, Inc. $ILMN

Wealthcare Advisory Partners LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 41.1% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,916 shares of the life sciences company’s stock after purchasing an additional 2,598 shares during the quarter. Wealthcare Advisory Partners LLC’s holdings in Illumina were worth $851,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. lifted its holdings in shares of Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock worth $465,000 after buying an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Illumina by 3.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 164 shares during the period. Nissay Asset Management Corp Japan ADV raised its stake in Illumina by 0.9% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,362 shares of the life sciences company’s stock worth $1,774,000 after purchasing an additional 207 shares in the last quarter. Rise Advisors LLC boosted its holdings in Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Finally, Farther Finance Advisors LLC grew its position in shares of Illumina by 9.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 2,521 shares of the life sciences company’s stock worth $241,000 after purchasing an additional 225 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of Illumina stock opened at $97.78 on Thursday. The company’s 50 day moving average price is $98.47 and its two-hundred day moving average price is $90.11. The firm has a market capitalization of $15.03 billion, a P/E ratio of 12.38, a P/E/G ratio of 2.33 and a beta of 1.40. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina’s revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ILMN shares. Evercore ISI lowered their target price on shares of Illumina from $135.00 to $132.00 and set an “outperform” rating on the stock in a report on Tuesday. Canaccord Genuity Group raised their price objective on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research note on Friday, August 1st. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and cut their target price for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Royal Bank Of Canada set a $124.00 target price on Illumina in a report on Tuesday, September 2nd. Finally, Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $123.56.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.